“We are pleased with the FDA's decision to grant Fast Track Designation for CAN-2409 in pancreatic cancer,” said Paul Peter Tak, MD, PhD, FMedS...
RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...
“As part of the pioneering team that established RNAi therapeutics as a whole new class of medicines, I am thrilled to see the field advance with six...
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously challenging and aggressive form of cancer, usually diagnosed in advanced stages, making curative t...
This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modul...
This development underscores the company's commitment to advancing innovative solutions that provide relief and improved quality of life for the millions o...
This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Additional...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, announced the introduction of Simcyp™ Biopharmaceutics software. It is designed...
Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TMdrug delive...
- First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – &l...
The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...
© 2024 Biopharma Boardroom. All Rights Reserved.
